Assertion: designation | /r/HasProperty | received investigational exemption
Facets:
Source sentences:
text: A description of the product, including: Classification, name of the product and all component products, if applicable (3.7(c)(2)(i)); Common, generic, or usual name of the product and all component products (3.7(c)(2)(ii)); Proprietary name of the product (3.7(c)(2)(iii)); Identification of any component of the product that already has received premarket approval, is marketed as not being subject to premarket approval, or has received an investigational exemption, the identity of the sponsors, and the status of any discussions or agreements between the sponsors regarding the use of this product as a component of a new combination product (3.7(c)(2)(iv)); Chemical, physical, or biological composition (3.7(c)(2)(v)); Status and brief reports of the results of developmental work, including animal testing (3.7(c)(2)(vi)); Description of the manufacturing processes, including the sources of all components (3.7(c)(2)(vii)); Proposed use or indications (3.7 (c)(2)(viii)); Description of all known modes of action, the sponsor’s identification of the single mode of action that provides the most important therapeutic action of the product, and the basis for that determination (3.7(c)(2)(ix)); Schedule and duration of use (3.7(c)(2)(x)); Dose and route of administration of drug or biologic (3.7(c)(2)(xi)); Description of related products, including the regulatory status of those related products (3.7(c)(2)(xii)); and Any other relevant information (3.7(c)(2)(xiii)).
text: Identification of any component of the product that already has received premarket approval, is marketed as not being subject to premarket approval, or has received an investigational exemption.